君实生物：关于JS207用于非小细胞肺癌患者新辅助治疗的Ⅱ/Ⅲ期临床试验申请获得FDA批准的公告

Core Viewpoint - Junshi Biosciences announced the approval of its clinical trial application for JS207, a humanized anti-PD-1 and VEGF bispecific antibody, by the U.S. FDA for a Phase II/III study in patients with resectable, AGA-negative non-small cell lung cancer [1] Group 1 - The clinical trial is an open-label, two-arm, randomized, positive-controlled study [1] - The study compares JS207 with Nivolumab in the neoadjuvant treatment setting [1] - The focus is on patients with AGA-negative non-small cell lung cancer [1]